Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Retinoblastoma
and you are
between 2 and 10
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Postoperative Treatment of Unilateral Retinoblastoma After Primary Enucleation according to histopathological risk factors of the International Retinoblastoma Staging Working Group.

Provided treatments

  • Other: Observation
  • Drug: Etoposide
  • Drug: Vincristine
  • Radiation: Orbital irradiation
  • Drug: Carboplatin
  • Drug: Vincristine
  • Drug: Cyclophosphamide
  • Drug: Carboplatin
  • Drug: Etoposide
  • Drug: Carboplatin
  • Drug: Thiotepa
  • Drug: Vincristine
  • Drug: Cyclophosphamide
  • Procedure: Cytapheresis
  • Drug: Carboplatin
  • Drug: Etoposide
  • Drug: Thiotepa
  • Procedure: Peripheral bood stem cell transplantation
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02870907. The sponsor of the trial is Institut Curie and it is looking for 185 volunteers for the current phase.
Official trial title:
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated